Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study

References

• CarboneMKratzkeRATestaJRThe pathogenesis of mesotheliomaSemin Oncol2002291217
   PubMed Web of Science ®Google Scholar
• RøeODStellaGMMalignant pleural mesothelioma: history, controversy and future of a manmade epidemicEur Respir Rev20152413511513125726562
   PubMed Web of Science ®Google Scholar
• RamalingamSSBelaniCPRecent advances in the treatment of malignant pleural mesotheliomaJ Thorac Oncol2008391056106418758312
   PubMedGoogle Scholar
• VogelzangNJRusthovenJJSymanowskiJPhase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaJ Clin Oncol200321142636264412860938
   PubMed Web of Science ®Google Scholar
• RemonJReguartNCorralJLianesPMalignant pleural mesothelioma: new hope in the horizon with novel therapeutic strategiesCancer Treat Rev2015411273425467107
   PubMed Web of Science ®Google Scholar
• CovaEColomboMInghilleriSAntibody-engineered nanoparticles selectively inhibit mesenchymal cells isolated from patients with chronic lung allograft dysfunctionNanomedicine201510192324559038
   PubMedGoogle Scholar
• CovaEInghilleriSPandolfiLBioengineered gold nanoparticles targeted to mesenchymal cells from patients with bronchiolitis obliterans syndrome does not rise the inflammatory response and can be safely inhaled by rodentsNanotoxicology201711453454528415888
   PubMed Web of Science ®Google Scholar
• BrustMWalkerMBethellDSchiffrinDJWhymanRSynthesis of thiolderivatised gold nanoparticles in a two-phase Liquid–Liquid systemJ Chem Soc Chem Commun199477801802
   Google Scholar
• PellegrinoTMannaLKuderaSHydrophobic Nanocrystals Coated with an Amphiphilic Polymer Shell: A General Route to Water Soluble NanocrystalsNano Letters200444703707
   Web of Science ®Google Scholar
• ScottBRAlexandraCRRichardGMPemetrexed indirectly activates the metabolic kinase AMPK in human carcinomasCancer Res20107024102991030921159649
   PubMedGoogle Scholar
• MorfouaceMShelatAJacusMPemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastomaCancer Cell201425451652924684846
   PubMed Web of Science ®Google Scholar
• FaoroVFinkBTaudorfSAcute in vitro hypoxia and high-altitude (4,559 m) exposure decreases leukocyte oxygen consumptionAm J Physiol Regul Integr Comp Physiol20113001R32R3920962205
   PubMedGoogle Scholar
• Mrakic-SpostaSGussoniMMontorsiMPorcelliSVezzoliAAssessment of a standardized ROS production profile in humans by electron paramagnetic resonanceOxid Med Cell Longev201220123110
   Google Scholar
• PhilippeauxMMPacheJCDahounSEstablishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysisHistochem Cell Biol2004122324926015372243
   PubMedGoogle Scholar
• SatoAToriiIOkamuraYImmunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesotheliumMod Pathol201023111458146620657552
   PubMedGoogle Scholar
• MinatoHKuroseNFukushimaMComparative immunohistochemical analysis of IMP3, GLUT1, EMA, CD146, and desmin for distinguishing malignant mesothelioma from reactive mesothelial cellsAm J Clin Pathol20141411859324343741
   PubMed Web of Science ®Google Scholar
• DubeySSchillerJHThree emerging new drugs for NSCLC: pemetrexed, bortezomib, and cetuximabOncologist200510428229115821248
   PubMed Web of Science ®Google Scholar
• MiklánZOrbánEBánócziZHudeczFNew pemetrexed-peptide conjugates: synthesis, characterization and in vitro cytostatic effect on non-small cell lung carcinoma (NCI-H358) and human leukemia (HL-60) cellsJ Pept Sci2011171280581122076954
   PubMedGoogle Scholar
• MoriSChangJTAndrechekERAnchorage-independent cell growth signature identifies tumors with metastatic potentialOncogene200928312796280519483725
   PubMed Web of Science ®Google Scholar
• PandolfiLBelliniMVannaRH-Ferritin enriches the curcumin uptake and improves the therapeutic efficacy in triple negative breast cancer cellsBiomacromolecules201718103318333028886247
   PubMed Web of Science ®Google Scholar
• GuazzelliABakkerETianKDemonacosCKrstic-DemonacosMMuttiLPromising investigational drug candidates in phase I and phase II clinical trials for mesotheliomaExpert Opin Investig Drugs2017268933944
   PubMed Web of Science ®Google Scholar
• BaasPFennellDKerrKMMalignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201526Suppl 5v31v3926223247
   PubMed Web of Science ®Google Scholar
• EttingerDSWoodDEAkerleyWNCCN guidelines insights: malignant pleural mesothelioma, version 3.2016J Natl Compr Canc Netw201614782583627407123
   PubMed Web of Science ®Google Scholar
• RollinsKDLindleyCPemetrexed: a multitargeted antifolateClin Ther20052791343138216291410
   PubMed Web of Science ®Google Scholar
• VogelzangNJRusthovenJJSymanowskiJPhase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesotheliomaJ Clin Oncol200321142636264412860938
   PubMed Web of Science ®Google Scholar
• NowakAKChemotherapy for malignant pleural mesothelioma: a review of current management and a look to the futureAnn Cardiothorac Surg20121450851523977545
   PubMedGoogle Scholar
• BonelliMAFumarolaCLa MonicaSAlfieriRNew therapeutic strategies for malignant pleural mesotheliomaBiochem Pharmacol201712381827431778
   PubMedGoogle Scholar
• FoyezMOk-CheolJFarzanaAOral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancerJ Control Release201828416017029908222
   PubMedGoogle Scholar
• YangWYangLXiaYLung cancer specific and reduction-responsive chimaeric polymersomes for highly efficient loading of pemetrexed and targeted suppression of lung tumor in vivoActa Biomater20187017718529410335
   PubMed Web of Science ®Google Scholar
• StolarczykEUStolarczykKŁaszczMKubiszewskiMLeśAMichalakOPemetrexed conjugated with gold nanoparticles – Synthesis, characterization and a study of noncovalent interactionsEur J Pharm Sci2017109132028709909
   PubMed Web of Science ®Google Scholar
• KushitaniKAmatyaVJMawasASMiyataYOkadaMTakeshimaYUse of antinoxa antibody for differential diagnosis between epithelioid mesothelioma and reactive mesothelial hyperplasiaPathobiology2016831334026735863
   PubMed Web of Science ®Google Scholar
• KinoshitaYTakasuKYuriTTwo cases of malignant peritoneal mesothelioma without asbestos exposure: cytologic and immunohisto-chemical featuresAnn Diagn Pathol20131719910322784439
   PubMedGoogle Scholar
• YuichiKKoshoTTakashiYCytologic-pathologic correlation two cases of malignant peritoneal mesothelioma without asbestos exposure: cytologic and immunohistochemical featuresAnn Diagn Pathol20131719910322784439
   PubMedGoogle Scholar
• St CroixBCD146: the unveiling of a pro-angiogenic netrin receptorCell Res201525553353425849249
   PubMedGoogle Scholar
• HwangKEKimYSHwangYRPemetrexed induces apoptosis in malignant mesothelioma and lung cancer cells through activation of reactive oxygen species and inhibition of sirtuin 1Oncol Rep20153352411241925738249
   PubMedGoogle Scholar
• RelanVMorrisonLParsonsonKPhenotypes and karyotypes of human malignant mesothelioma cell linesPLoS One201383e5813223516439
   PubMedGoogle Scholar
• SakaguchiHIshidaHNitandaHYamazakiNKanekoKKobayashiKPharmacokinetic evaluation of intrapleural perfusion with hyperthermic chemotherapy using cisplatin in patients with malignant pleural effusionLung Cancer2017104707428213004
   PubMed Web of Science ®Google Scholar
• TadaYHiroshimaKShimadaHAn intrapleural administration of zoledronic acid for inoperable malignant mesothelioma patients: a phase I clinical study protocolSpringerplus20165119527026891
   PubMedGoogle Scholar
• StermanDHAlleyEStevensonJPPilot and feasibility trial evaluating immunogene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFNα combined with chemotherapyClin Cancer Res201622153791380026968202
   PubMed Web of Science ®Google Scholar
• AndoHKobayashiSAbu LilaASAdvanced therapeutic approach for the treatment of malignant pleural mesothelioma via the intrapleural administration of liposomal pemetrexedJ Control Release2015220Pt A293626476173
   PubMed Web of Science ®Google Scholar
• OrlandiEMordentiPZangrandiACavannaLIntrapleural trastuzumab therapy for malignant pleural effusion from her 2 overexpression in metastatic gastric cancerChemotherapy2014605–632132426279275
   PubMedGoogle Scholar
• OhtaYShimizuYMatsumotoIWatanabeGManagement of malignant pleural effusion by multimodality treatment including the use of paclitaxel administered by 24-hour intrathoracic infusion for patients with carcinomatous pleuritisJ Exp Clin Cancer Res2006251151916761613
   PubMedGoogle Scholar
• StellaGCovaEInghilleriSPemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study [abstract]Eur Respir J201546Suppl 59
   Google Scholar